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ABSTRACT  Despite the intensive research of the last three decades into Transient Receptor Potential 
(TRP) cation channels, no precise and complete profiling of these channels is yet available regard-
ing their involvement in physiopathology and carcinogenesis in particular. TRP channel activity is 
crucial for all the essential hallmarks of carcinogenesis such as proliferation, apoptosis, migration 
and angiogenesis, which is the reason why these channels have been proposed not only as clinical 
markers, but also as promising targets for anti-cancer therapy. However, in the majority of stud-
ies, each channel has been considered as a separate molecular entity and studied independently 
from the other TRPs, while a complete “transportome” of the specific stages of carcinogenesis is 
required for the effective use of these targets. This review focuses on the partial TRP expression 
profiles found in the literature and the means by which a full TRP signature could be achieved. 
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Introduction
The study of changes in the expression pattern during phys-
iopathological transitions and disease progression is of crucial 
importance in understanding the development of many pathologies 
such as carcinogenesis. It has been shown that some genes are 
either switched “on” and “off”, or are deregulated during the de-
velopment of many cancers, and the altered expression of certain 
genes entails cancer growth and metastasis. The acquisition of a 
malignant tumor phenotype is the result of enhanced cell prolif-
eration and migration, aberrant differentiation and increased cell 
survival, resulting in expansion and invasion of the surrounding 
tissues. Such a transformation is often accompanied by changes 
in gene expression and consequently, by abnormal cellular re-
sponses in which they are involved (Gkika and Prevarskaya, 2011; 
Hanahan and Weinberg, 2011; Nilius et al., 2007; Fiorio Pla and 
Gkika, 2013). Being involved in nearly all ‘cancer hallmarks’, there 
is an increasing consensus on the idea that ion channels play a 
significant role in driving cancer progression at all stages, as shown 
by the increasing number of reviews focusing on the role of ion 
channels and transporters (collectively defined as “transportome”). 
Accumulating evidence tends to demonstrate that the development 
of some cancers could also involve such ion channel deregulation 
and therefore, could be classified as channelopathies (Munaron 
and Arcangeli, 2013; Pedersen and Stock, 2013). Among the dif-
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ferent ion channels, TRP (Transient Receptor Potential) channels 
have attracted a huge attention since their discovery: TRPs are 
expressed in almost all tissues and are polymodal molecular sen-
sors in the regulation of various cell functions, having profound 
effects on a variety of physiological and pathological processes. It 
is therefore not surprising that TRP channels play a critical role in 
cancer progression and their functional expression characterizes 
the phenotype of a tumor (Gkika and Prevarskaya, 2011). 
TRP channels form a relatively young ion channel family, as 
they were first described in Drosophila in 1989 (Montell and Rubin, 
1989), when photoreceptors carrying trp gene mutations exhibited 
a transient voltage response to continuous light (Montell and Rubin 
1989). Since then, about thirty TRP channels have been identified 
and classified into six families: TRPC (Canonical), TRPV (Vanil-
loid), TRPM (Melastatin), TRPML (Mucolipin), TRPP (Polycystin), 
and TRPA (Ankyrin) (Montell et al., 2002). TRP channels are 
putative six transmembrane polypeptide subunits that assemble 
as tetramers to form cation-permeable pores permeable to Ca2+, 
with the exceptions of TRPM4 and TRPM5, which are only per-
meable to monovalent cations. TRP channels are exceptional as 
they display an impressively wide spectrum of specific activation 
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and regulation mechanisms, responding to many external stimuli 
including light, sound, chemicals, temperature, and touch, as well 
as, to alterations in cell environment, activation of several kinases 
or interaction with intracellular proteins. 
The enormous functional potential of TRPs might be especially 
important for our understanding of the pathogenesis of several 
diseases, and therefore TRP channels have been identified as new 
potential therapeutic drug targets. Indeed, TRP channels are asso-
ciated with several pathological processes, which include (but are 
not limited to) pain, cardiovascular, pulmonary and skin diseases, 
inflammation, obesity, proliferative diseases via dysregulation of the 
cell cycle, carcinogenesis and tumor angiogenesis (Gkika and Pre-
varskaya, 2009; Gkika and Prevarskaya, 2011; Moran et al., 2011; 
Nilius and Owsianik, 2010; Prevarskaya et al., 2007; Prevarskaya 
et al., 2011). There are some gene mutations that correlate TRP 
channels and pathogenesis, but the pathological potential of TRPs 
mostly depends on the availability of functional channel units in the 
spatiotemporal cell context. Altered expression of these channels 
causes abnormal progression of a number of cellular responses, 
including cell proliferation, survival, migration and apoptosis (Fio-
rio Pla and Munaron, 2014; Monteith et al., 2012). Even though 
there is growing evidence that TRP channels constitute a novel 
area of research, being important molecular actors of numerous 
physiopathological processes, the tissue- and disease-specific 
expression profile of TRP channels is yet incomplete. 
The aim of this review is to gather together the existing informa-
tion on TRP expression profiles and to explore the means by which 
the definition of a TRP signature in carcinogenesis of different 
tissues can be achieved.
A great effort has already been dedicated by several authors 
to gather together information on TRP channel expression in a 
variety of models and to summarize them in review articles. These 
collections focus either on single cancer types, including brain 
tumors (Schonberg et al., 2012) and hematologic malignancies 
(Morelli et al., 2013), or on a single biological process involved in 
cancer, such as migration (Fiorio Pla and Gkika, 2013), autophagy 
(Kondratskyi et al., 2013), and tumor vascularization (Fiorio Pla 
et al., 2012; Fiorio Pla and Munaron, 2014; Moccia, 2012; Moccia 
et al., 2014), or use a multi-disease view to profile TRP functional 
expression (Nilius, 2007). However, a full profiling of TRP channels 
is still required in order to provide a cancer-specific pattern, allow-
ing a correlation of TRP channel expression patterns to specific 
stages of carcinogenesis. 
Over the last few decades, various technologies have been 
established to discover the expression pattern of cells and tissues, 
and their changes. The conventional quantitative PCR approaches 
(real time qPCR, Taqman real time PCR) are still the most used to 
screen TRP channel expression in tissues and cells. As an example, 
TRP screening of human TRPCs or TRPMs, were performed in 
order to profile the expression in several normal tissues (Fonfria et 
al., 2006; Riccio et al., 2002). The data documented a systematic 
quantification of selected TRP channels in broad range of human 
tissue providing useful information to compare the expression of 
selected population of TRP channels. However, this approach is 
by definition low throughput screening and therefore not sufficient 
to detect the expression of all the TRPs in the same samples. 
At present, several high throughput technologies are available 
to simultaneously identify and quantify the unique pattern of ex-
pressed genes within different biological samples. High throughput 
screening (HTS) is thus the key to large-scale RNA profiling of 
physiopathological transitions, enabling the identification of dif-
ferentially expressed genes and thus provide novel therapeutic 
targets (Wang et al., 2009). Currently available methods to HTS 
of gene expression range from RNA-Seq to microarrays, including 
even more recent technologies such as gene trapping and digital 
qPCR (Life TechnologiesTM). 
Notably, the vast amount of datasets originating from HTS 
studies can be deposited and either directly analyzed by users or 
interrogated through bio-informatic tools that rely on advanced com-
putational algorithms to cluster data, allowing a user-customizable 
exploration. These computational tools are search engines that 
can browse for user’s query gene(s) in all the datasets present in 
public repositories, for a specific biological area of interest and in 
a defined organism or model. 
One of the most known tools to browse cancer gene expres-
sion is Oncomine® (www.oncomine.org), a platform designed by 
researchers at the University of Michigan (US) and later acquired 
by Life Technologies (Rhodes et al., 2004). This platform offers 
the analysis of more than 700 independent datasets to compute 
gene expression signatures, clusters, and gene-set modules. 
Oncomine® allows co-expression analysis of different genes or 
differential analysis to compare (i) gene expression in a cancer 
tissue to that of its healthy counterpart; (ii) cancers originating in 
different tissues; (iii) different stages of a given cancer, (iv) expres-
sion signature of two normal tissues. 
Another tool for the consultation of HTS datasets is BioGPS 
(Wu et al., 2009), a portal that allows query search through an 
index of most of the major gene identifiers (including Entrez Gene, 
Ensembl, Refseq, Affymetrix), or even by genome location in a 
specific chromosomal position. The output is the expression pat-
tern of the query gene in the chosen data set and a gene report 
providing a fraction of all that is known about that gene function. 
Finally, the most recent informatic tool presented for dataset 
interrogation is SEEK (search-based exploration of expression 
compendia), a query-based search engine developed by the 
Department of Computer Science of Princeton University (US) 
(Zhu et al., 2014). SEEK uses a query-level based algorithm to 
explore an expression compendia that includes 155,025 experi-
ments spanning 5,210 data sets from 41 different microarray and 
RNA-seq platforms. SEEK explores individual data sets to establish 
associations between co-expressed genes and biological variables 
and can refine search results limiting data sets to a specific tissue 
or disease; the interface then visualizes the results by user-friendly 
features, such as heat maps. 
The cluster analysis and visualization software GeneXPress, 
developed by Standford University and freely downloadable for 
academic use, allows an examination of an expression compen-
dium of 1,975 published microarrays spanning 22 tumor types. 
The compendium was analyzed in order to establish expression 
profiles in different tumors by extracting ‘active modules’, meant as 
sets of genes involved in a specific cell function (http://ai.stanford.
edu/~erans/cancer/genexpress.html). Gene Atlas U133A dataset 
interrogates the expressions of thousands of protein-encoding 
human and mouse genes and to profile 79 human and 61 mouse 
tissues (Su et al., 2004). Unfortunately, only a few tumor tissues 
were screened among all the tissues analyzed, including colorec-
tal-adenocarcinoma, Burkitt’s lymphoma and various leukemia 
subtypes. Therefore the Gene Atlas database is not suitable to 
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compare expression patterns between normal and tumor coun-
terparts of a same tissue origin and to hypothesize the presence 
of putative oncogenic or oncosuppressor proteins involved in a 
physiopathological transition. 
Screening TRP expression in normal tissues
Over the last decade, a few articles have reported the screening 
of a various number of tissues and/or cell lines for the expression 
of TRP channels. These studies contain very important informa-
tion as they reveal the specific expression pattern of a panel of 
query genes in a given set of tissues or models. However, the data 
available is limited, as not all the TRP families have been taken 
into account and, not less important, the set of samples screened 
is often incomplete for a given physiopathological transition and 
for the different stages of disease progression. For example, if we 
are interested in prostate cancer development and the interest is 
to investigate expression of the TRP channels inside this model, 
we are not able to find studies screening the complete expression 
pattern of these proteins throughout all stages of tissue transition 
from the normal to the most advanced aggressive phenotype. 
As an example, Riccio et al., investigated the mRNA distribu-
tion of human TRPCs in a discrete number of tissues, including 
the central nervous system (CNS), peripheral tissues as well as 
a panel of commonly used cell-lines. By means of TaqMan real-
time quantitative RT-PCR, they observed a distinctive pattern of 
distribution in the tissues analyzed for each queried gene. A wide 
distribution of TRPC1 was observed in all the tissues screened, 
where instead TRPC3 and TRPC5 were more abundant in CNS. 
TRPC4 had high expression levels in brain, bone, heart and pros-
tate, whereas TRPC7 was mainly found in placenta and lung. For 
what concerns the cell line screening, TRPC expression profile 
was distributed in a cell-specific manner. For instance, TRPC1 
mRNA was detected in all the cell lines tested, while, TRPC3 and 
TRPC6 were only detected in HEK-293 cells (Riccio et al., 2002). 
On the other hand, the distribution pattern of the human TRPM 
family was analyzed in the central nervous system (CNS) and 
peripheral tissues, comparing results from both TaqMan and real 
Fig. 1. Analysis of TRP ankyrin, canonical, melastatin and vanilloid families in the Gene Atlas 
U133A dataset by BioGPS in normal prostate and kidney tissues. Data taken from BioGPS.org 
time RT-PCR approaches, showing a TRPM 
tissue-specific expression profile (Fonfria 
et al., 2006). The results show a differential 
expression of the channels, with TRPM 2, 
4, 5, 6, and 7 being widely distributed in the 
CNS and periphery. Brain tissue showed 
high levels of expression of TRPM1, TRPM2, 
TRPM3 and TRPM6; TRPM4, TRPM5 and 
TRPM8 were preferentially expressed in 
prostate, while the most expressed genes 
in the intestine were TRPM4, TRPM5 and 
TRPM6. The expression of TRPM7 was 
widely distributed throughout the tissues, 
and particularly high levels of TRPM7 mRNA 
were found in heart, pituitary, bone, and 
adipose tissue.
In addition to literature, recourse is pos-
sible to bioinformatics tools (see previous 
paragraph) in an attempt to profile TRP chan-
nel expression in various tissues. Although 
TRP expression is ubiquitous in human, 
current data available in literature suggests a 
tissue-specific expression signature for some 
members of this gene family. However, there 
is still lack of a precise expression pattern for 
each tissue and disease condition. Bioinfor-
matics tools gather together expression data, 
which may be used in the attempt to obtain 
a TRP signature for our model of study. As 
an example, we browsed Gene Atlas U133A 
through the BioGPS tool for the expression 
of all the 6 TRP sub-families in two given tis-
sues of interest, such as kidney and prostate 
epithelium, and obtained expression data for 
most of the TRPs (Fig. 1). The first conclu-
sion is that the pattern obtained is clearly 
incomplete, as TRPP and TRPML families 
are not taken in to account. Concerning the 
TRPs screened (TRPC, TRPV, TRPM fami-
lies and TRPA1), we observed a detectable 
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expression of all the TRP channels present in the database in both 
tissues. Interestingly, TRPV6 is highly expressed in both prostate 
and kidney tissues as previously detected (Van Haute et al., 2010; 
Nijenhuis et al., 2003; Peng et al., 2001), while TRPM4 is highly 
expressed only in prostate samples, again confirming the literature 
data (Van Haute et al., 2010; Launay et al., 2002; Nilius et al., 2003). 
It has to be noticed that other reports showed a barely detectable 
expression of TRPV6 channel in normal prostate epithelium as 
compared with benign prostate hyperplasia and cancer (Fixemer 
et al., 2003; Lehen’kyi et al., 2007). 
Although the data obtained by the use of these databases are 
highly informative, this sort of analysis is far from being complete 
since the expression of all TRP channels (TRPMLs, TRPPs) is 
not taken into account in the dataset and the message cannot be 
completely understood as it is isolated from its physiological context. 
TRP expression in cancer
A vast number of studies has demonstrated that carcinogenesis 
and tumor progression to late stages of several cancers are often 
characterized by changes in TRP channel expression. Indeed, 
several research articles have shown the role of some TRP chan-
nels in cancer. The main cancer types for which a role of TRPs 
has been shown are melanoma, prostate, breast, kidney, bladder 
carcinomas and glioma (Gkika and Prevarskaya, 2009; Natalia 
Prevarskaya et al., 2007).
Malignant melanoma is the most aggressive skin tumor and 
develops in melanocytes, from normal skin or benign moles, as 
well as in the eye. Melanoma is dangerous when not found in the 
early stages and is the cause of 75% of skin cancer-related deaths. 
TRPM1, the founding member of melastatin TRP family, has been 
identified as a melanoma metastasis suppressor that is exclusively 
expressed in normal pigment cells (skin and eye) and in melanoma 
cells, while it is downregulated in metastatic melanoma (Duncan 
et al., 1998; Fang and Setaluri, 2000). The inverse correlation 
between TRPM1 mRNA and the metastatic phenotype represents 
a diagnostic marker of the aggressiveness of melanoma. Thus, 
TRPM1 is a putative tumor suppressor, although its role in the 
regulation of melanoma progression is not yet understood (Devi 
et al., 2009; Nilius et al., 2007). 
Prostate cancer (PCa) is the most common non-cutaneous hu-
man malignancy and the second most lethal tumor among men, with 
the highest incidence in industrialized countries. Whilst biomarker 
detection is becoming ever more sensitive, available treatments 
are limited, notably for high-grade tumors. Surgical resection, pro-
posed for localized prostate tumors, has severe consequences for 
patients. Initially, tumors develop from epithelial cells and remain 
androgen-dependent. Therefore, once the disease has progressed 
and become highly invasive or metastatic, the reduction of the 
circulating levels of androgens by castration or the administration 
of androgen antagonists is the standard treatment. However, its 
efficiency is time-limited and tumors inescapably become refractory 
to hormonal treatments, leading to more than 200,000 deaths per 
year around the world. Furthermore, PCa is most likely to spread 
to the bone and bone metastases are generally more difficult to 
cure. At present, the expression profile of TRP channels in pros-
tate carcinogenesis has not been yet completed, and the specific 
functional roles for most of these are only just beginning to be 
understood. In particular, we and other research groups have pro-
vided evidence regarding the role of TRP channels on PCa (Gkika 
and Prevarskaya, 2011; Van Haute et al., 2010; N Prevarskaya et 
al., 2007). In particular, we clarify the role for four TRP members, 
TRPV2, TRPV6, TRPC6 and TRPM8, suggesting them as very 
promising players since their expression and/or activity mark and 
regulate specific stages of PCa (Flourakis and Prevarskaya, 2009; 
Gkika and Prevarskaya, 2009; Prevarskaya et al., 2011; Skryma 
et al., 2011; Gkika et al., 2015). TRPV2 is expressed in androgen-
independent prostate cancer cells and TRPV2 mRNA level is 12 
times higher in patients presenting metastatic cancer than in patients 
with non-metastatic prostate cancer. TRPV2 has been shown to 
increase cell migration when overexpressed in androgen-dependent 
LnCap cells, while its down-regulation in androgen-independent 
PC3 cells reduced growth and invasiveness of xenograft tumors. 
TRPV2 role in the progression of prostate androgen-dependent 
cancer to an aggressive castration-resistant phenotype is related 
to its constitutive activation and consequent increased level of 
cytosolic [Ca2+], increasing proliferation and migration if cancer 
cells (Monet et al., 2010). TRPV6 is proposed as a prognostic 
marker of prostate cancer, as its expression is barely detectable 
in normal tissues and benign prostate hyperplasia, but increases 
in high-grade adenocarcinomas. TRPV6 is highly expressed in 
the androgen-dependent human prostate cancer LNCaP cell line, 
where it has been shown to support cell proliferation through Ca2+-
dependent activation of nuclear factor of activated T cell (NFAT) 
pathway. Together with TRPV6, TRPC6 also activates proliferation 
via the NFAT pathway, by agonist-mediated stimulation of alpha1-
adrenergic receptors of primary human prostate cancer epithelial 
(hPCE) cells (Thebault et al., 2006). Besides TRPV2, TRPV6 
and TRPC6, TRPM8 has emerged as an important factor in PCa 
cell migration and tumor progression: TRPM8 expression at the 
plasma membrane level is up-regulated in early-stages prostate 
cancer (PCa), and then decreases with tumor progression to the 
late, invasive, androgen-insensitive stage (Gkika and Prevarskaya, 
2009). Also, it has been recently demonstrated that PSA activates 
TRPM8 current by inducing the accumulation of functional channels 
in the plasma membrane, reducing prostate cancer cell migration 
(Gkika et al., 2010). TRPM8 could thus sustain dormancy of pros-
tatic hyperplasia via PSA activation, reducing cell motility and the 
gradual loss of TRPM8 during tumor progression to a late stage 
could be an escape mechanism of escape adopted by the tumor 
(Bidaux et al., 2007; Gkika et al., 2015).
Breast cancer is the second leading cause of death related to 
cancer in women. Once again, different studies have highlighted 
the role of some TRP channels in the evolution of breast carcinoma. 
TRPC6 and TRPV6 are strongly expressed in breast tumor com-
pared to normal breast tissue and they play a pro-proliferative role. 
The estrogen receptor antagonist tamoxifen reduces the expression 
of TRPV6 and the inhibition of TRPV6 calcium transport activity 
has a strong influence on breast cancer cell proliferation (Bolanz 
et al., 2008). TRPC3 and TRPC6 co-localize and are significantly 
upregulated in metastatic breast cancer cells, compared to normal 
breast tissue. Moreover, silencing of TRPC6 in highly metastatic 
breast cancer cells results in a significant reduction of cell growth 
(Aydar et al., 2009).
Also for bladder carcinoma, the fourth most common cancer 
and the eighth highest cancer-related cause of mortality in men, 
some TRP channels have been shown to play a key role during 
carcinogenesis. TRPV1 is downregulated during the progression 
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of bladder transitional cell carcinoma (TCC) towards its aggres-
sive phenotype, and thus represents a negative prognostic factor 
for TCC patients (Amantini et al., 2009). TRPV2 and TRPM7 are 
negative regulators of bladder cancer cell proliferation in MBT-2 
mouse cells, and were both overexpressed when compared to 
normal mouse urothelial cells (Mizuno et al., 2014). Moreover, 
TRPV2 activation leads to human T24 bladder cancer apoptosis, 
possibly through excess Ca2+ influx causing Ca2+ overload, indicating 
that TRPV2 negatively regulates bladder cancer cell proliferation 
(Yamada et al., 2010).
In renal cell carcinoma (RCC), the most common cancer of the 
lining of the proximal tubule in the kidney, Song et al., investigated the 
dent on vascularization, which is promoted by the same tumor cells 
upon secretion of a number of growth factors. Vessel formation is 
a complex multistep process during which ‘activated’ endothelial 
cells (ECs), the first mechanical and functional interface between 
blood and tissues, proliferate, migrate, differentiate and are stabi-
lized in a new circulatory network (Carmeliet, 2005; Folkman, 2006; 
Folkman, 2007). ECs were previously considered to be genetically 
stable compared with tumor cells and therefore an ideal therapeutic 
target in the development of anti-angiogenic treatments. However, 
their stability has been questioned by several studies showing 
that tumor-derived endothelial cells (TECs), as well as pericytes, 
differ significantly from their normal counterparts at genetic and 
Fig. 2. Expression of TRPA1, TRPC1, 
TRPC3, TRPC6, TRPV6 and TRPP2 
analyzed by Su I. and colleagues by 
Affymetrix U95a GeneChip. Values are 
represented in terms of mean ± STD of 
the normalized expression values depos-
ited on Primary Tumors (U95) Data set 
downloadable on BioGPS.org
role of TRPC6. TRPC6 was highly 
expressed in RCC tissues compared 
with normal renal samples, and the 
expression was directly correlat-
ing with tumor stage. Inhibition of 
TRPC6 expression in human renal 
adenocarcinoma ACHN cells sup-
pressed proliferation and prolonged 
RCC cells G2/M phase transition, 
suggesting TRPC6 channel as a 
key regulator of RCC development 
(Song et al., 2013). Also TRPM3 has 
been shown to play a role in RCC 
development, promoting growth 
of clear cell renal cell carcinoma 
(ccRCC) and stimulating autophagy 
MAP1LC3A (LC3A) and MAP1LC3B 
(LC3B) (Hall et al., 2014).
Gliomas are tumors arising from 
glial cells of central and peripheral 
nervous systems, accounting for 
around one third of SNC tumors 
and around 80% of malignant brain 
tumors. In glioma tissues, cell lines 
and primary glioma cells, TRPV2 
expression decreases during tumor 
progression to late stages. TRPV2 
negatively regulates proliferation 
and resistance to apoptosis of 
U87MG glioma cells (Nabissi et al., 
2010). The same group also reported 
a role for TRPV1 as a mediator of 
glioma cell apoptosis, as its expres-
sion falls is reduced with glioma 
grading, suggesting TRPV1 as a 
positive marker for glioma prognosis 
(Amantini et al., 2007).
On the other hand, cancer growth 
and metastasis are strictly depen-
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functional levels (Bussolati et al., 2011; Nanda and St Croix, 2004). 
In this regard, few papers have compared the expression profile of 
TEC versus their healthy counterpart defining several differentially 
expressed gene families (Bhati et al., 2008; Ghilardi et al., 2008). 
Nonetheless, although the expression and role of TRP channels 
in the vascular endothelium is well recognized and is subject of a 
number of recent reviews (Nilius and Droogmans, 2001; Yao and 
Garland, 2005), only recently TRPs have been recognized as major 
players in tumor vascularization (Fiorio Pla et al., 2012b; Fiorio Pla 
et al., 2012; Fiorio Pla and Gkika, 2013). 
In the light of TEC abnormalities, knowledge of differential 
gene expression between tumor derived and normal ECs is of 
great importance to better understand the functional properties of 
tumor endothelium and could be relevant for the development of 
antiangiogenic anticancer therapeutic strategies. Such information 
would surely give a more complete view of the role of TRP chan-
nels in tumor progression. 
TRP expression in cancer through HTS datasets
Due to their important role in tumor progression, the need to 
establish a type- and stage-specific signature of TRP channels in 
cancer becomes even more evident. In 2001, Su et al., published 
a large-scale RNA profiling of primary carcinomas originating from 
different tissues, including prostate, breast, lung, ovary, colon, 
kidney, liver, pancreas, bladder, and gastroesophagus (Su et al., 
2001). Affymetrix U95a GeneChip was used to screen more than 
100 tumor tissue samples and their normal tissue counterparts to 
identify gene subsets whose expression is characteristic of specific 
tumor type. Since the raw data provided by this screening (Hu-
man Primary Tumors U95) is downloadable on http://biogps.org/
downloads/ for further analysis, we interrogated the dataset and 
found that among all genes screened, only six of the 28 existing 
TRP channels were identifiable, namely: TRPA1, TRPC1, TRPC3, 
TRPC6, TRPV6 and TRPP2. In Fig. 2, we report the expression 
of these genes in 8 out of 9 of the tumor tissues, and respective 
normal counterparts, screened by Su I. and colleagues: prostate, 
breast, kidney, pancreas, lung, liver, colon and gastroesphagous. 
For TRPC1, we observed a slightly lower level in all tumors tissues, 
except pancreas and liver, than in healthy tissues. Conversely, a 
higher level of TRPC1 channel expression has been reported in 
colorectal carcinoma cells (Sobradillo et al., 2014) as well as in 
MCF-7 human breast cancer cells (El Hiani et al., 2009) than in 
normal cells. Accordingly, overexpression of TRPC1 is reported 
in pancreas cancer and suppression of TRPC1 expression sig-
nificantly reversed TGF-b-induced motility in BxPc3 pancreatic 
adenocarcinoma cells (Dong et al., 2010).
In line with literature (Fixemer et al., 2003), we also noted that 
TRPV6 is highly overexpressed in prostate tumor compared to 
normal tissues. However, in healthy kidney the data obtained 
from Su et al., (Su et al., 2001) showed some discrepancies in 
the relative level of TRPV6 expression, when compared with 
that reported in the GeneAtlas database (Fig. 1). In this regard, 
TRPV6 indeed shows low levels of expression, if compared with 
TRPC1 for instance, while in GeneAtlas database TRPV6 is highly 
overexpressed compared to the screened TRP channels. High 
expression levels of TRV6 and TRPC6 are reported in literature for 
breast cancer (Bolanz et al., 2008; Peters et al., 2012) and here the 
findings from Su et al., were consistent with this, as the database 
presented a slight increase in TRV6 and TRPC6 expression in 
breast tumor samples (Fig. 2). As reported by Song et al., TRPC6 
is highly expressed in RCC tissues compared with normal renal 
tissue (Song et al., 2013). However, using the Affymetrix chip, Su 
et al., found a slight reduction in TRPC6 expression in RCC tumor 
tissues screened (Fig. 2)
All these discrepancies could be due to several reasons: first, 
a heterogeneity of the cohort of patient samples in terms of tumor 
staging; second, possible alteration of TRP channel expression 
profiles by clinical therapies, such as hormone deprivation therapy 
used for hormone-sensitive tumors (Bolanz et al., 2008; Gkika and 
Prevarskaya, 2011).
Moreover, it should be noticed that several alternative splicing 
isoforms of TRP channels are expressed within the cells, as in 
the case of TRPM8, TRPM4, TRPM1, TRPV1, TRPV2, TRPC6. 
Indeed, such isoform expression leads to functional diversity, which 
could thus alter cellular functions (Gkika and Prevarskaya, 2009; 
Van Haute et al., 2010; Launay et al., 2002; Nilius et al., 2003).
When screening TRP expression through large-scale RNA 
analysis methods or when simply exploring a HTS dataset, as for 
instance a microarray-based analysis, is therefore essential to refer 
to the probe set used in order to identify the isoforms of the gene 
that are detected. Most microarrays use probe sets composed 
of several probes to match a selected gene (16 per U95A-array 
probe set) in order to maximize the number of isoforms detected.
Conclusions
Being involved in nearly all of the ‘hallmarks of cancer’, as 
defined by Hanahan & Weinberg (Hanahan and Weinberg, 2011), 
there is an increasing consensus that TRP channels do indeed 
play a significant role in driving cancer progression at all stages 
(Liberati et al., 2013; Pla and Gkika, 2013). Therefore, quantitative 
and functional variations of ion channels in general, and TRPs in 
particular, disturb cellular physiological status (from a molecular 
point of view) and may lead to the incidence of a pathology defined 
‘channelopathy’. Therefore TRP channels may be seen as potential 
novel therapeutic, diagnostic, and prognostic targets for anti-cancer 
therapy. Although much effort has been put in gathering information 
regarding TRP expression and functional role in several tissues, as 
highlighted by the increasing number of reviews on this topic over 
recent years, a signature defining TRP channel expression pattern 
in tumors, distinguishable from that in healthy counterparts, is still 
incomplete. Such information would be of vital importance to better 
understand the molecular mechanisms involved in carcinogenesis 
and cancer progression to late aggressive stages.
Interestingly, a great amount of data describing the transcrip-
tomic profile during carcinogenesis has been produced in by HTS 
screening and is accessible through bioinformatics tools. Therefore, 
a focused re-analysis of TRP expression data contained in the 
compendia would shed new light in this field. As an example, here 
we focused on the re-analysis of the Primary Tumors Affimetryx 
GeneChip U95 previously published (Su et al., 2001). As well as 
confirming the literature data, all the information recovered could 
give assist in defining a new putative molecular target for prognosis/
therapy in cancer development. However, the information available 
is often incomplete and therefore the profile of TRP channels is 
far from being fully defined. For instance, only six out of the total 
28 TRP channels were probed in the Affimetryx GeneChip U95. 
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Nevertheless, other databases and bioinformatics tools are avail-
able and may possibly contain a more exhaustive probe set. We 
therefore propose the use of tools for exploiting datasets as a 
complementary approach to TRP profiling. 
In this review, we have summarized the data and bioinformatics 
tools that are available in order to have a global profile of TRP chan-
nels at the transcriptomic level. This approach can be of particular 
interest for defining a TRP signature during carcinogenesis that 
could be used as a biomarker set in cancer prognosis and diag-
nosis as well as providing anti-cancer targets. However, it should 
be noted that the transcriptomic profile requires validation not only 
at the protein expression level, but an exact protein localization at 
the sub-cellular level. Indeed, beyond the simple up- and down-
regulation of the expression of a particular TRP channel gene, 
alternative splicing enables the same gene to generate multiple 
mature mRNA types for translation, thus resulting in multiple channel 
protein isoforms. This leads to functional diversity, which may in 
turn have consequences on cellular functioning. Alternative splic-
ing generates protein isoforms with different biological properties, 
such as a change in functionality, protein/ protein interaction, or 
subcellular localization (Gkika and Prevarskaya, 2009). Thus, each 
cell cancer stage should be further characterized by a specific TRP 
signature on the spatio-temporal level, taking into account kinetics, 
magnitude and sub-cellular localization of channel activity.
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